Kristin Peck - Zoetis Executive VP and President of U.S. Operations

ZTS -- USA Stock  

USD 126.05  0.70  0.55%

  President
Ms. Kristin C. Peck is Executive Vice President and Group President, U.S. Operations, Business Development and Strategy of the Company. Ms. Peck has served as our Executive Vice President and Group President, U.S. Operations, Business Development and Strategy since March 2018, having previously served as our Executive Vice President and President, U.S. Operations from May 2015 to February 2018. From October 2012 through April 2015, she served as our Executive Vice President and Group President. Ms. Peck joined Pfizer in 2004 and held various positions, including Executive Vice President, Worldwide Business Development and Innovation Senior Vice President, Worldwide Business Development, Strategy and Innovation Vice President, Strategic Planning Chief of Staff to the Vice Chairman and Senior Director, Strategic Planning. Ms. Peck also served as a member of Pfizers Executive Leadership Team.
Age: 46  President Since 2018      
973-822-7000  http://www.zoetis.com
Peck holds a Bachelor degree from Georgetown University and a MBA from Columbia Business School.

Kristin Peck Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Joseph LaRosaRegeneron Pharmaceuticals
2019
Jay MarkowitzRegeneron Pharmaceuticals
2017
Scott JamisonPerrigo Company plc
2011
Jatin ShahPerrigo Company plc
2005
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
M RamanaDr Reddys Laboratories Ltd
2018
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Douglas McCorkleRegeneron Pharmaceuticals
2007
John HendricksonPerrigo Company plc
2016
Svend AndersenPerrigo Company plc
2017
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
K RaoDr Reddys Laboratories Ltd
2016
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Michael PariniVertex Pharmaceuticals Incorpor
2017
George YancopoulosRegeneron Pharmaceuticals
2016
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Marc CouckePerrigo Company plc
N/A
Ian SmithVertex Pharmaceuticals Incorpor
2017
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive VP and President of U.S. Operations
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
Linda Rhodes, Director
Frank DAmelio, Director
Robert Scully, Independent Director
Clinton Lewis, Executive VP and President of International Operations
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, President of RandD and Executive VP
Michael McCallister, Non-Executive Chairman of the Board
Paul Bisaro, Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Acting CFO and Sr. VP
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President CIO
Gregory Norden, Independent Director
Louise Parent, Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, CEO and Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 200 shares of
a day ago
Traded for 36.01
Purchased over 90 shares of
a day ago
Traded for 104.22
Purchased over 20 shares of
a day ago
Traded for 198.03
See also Your Current Watchlist. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.
Search macroaxis.com